Ye Shicheng, Boeter Jochem W B, Mihajlovic Marko, van Steenbeek Frank G, van Wolferen Monique E, Oosterhoff Loes A, Marsee Ary, Caiazzo Massimiliano, van der Laan Luc J W, Penning Louis C, Vermonden Tina, Spee Bart, Schneeberger Kerstin
Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine Utrecht University Uppsalalaan 8, Utrecht 3584 CT, The Netherlands.
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science Utrecht University Universiteitsweg 99, Utrecht 3584 CG, The Netherlands; Department of Biomedical Engineering Eindhoven University of Technology Postbus 513, Eindhoven 5600 MB, The Netherlands.
Adv Funct Mater. 2020 Jun 8;30(48):2000893. doi: 10.1002/adfm.202000893. eCollection 2020 Nov 25.
End-stage liver diseases are an increasing health burden, and liver transplantations are currently the only curative treatment option. Due to a lack of donor livers, alternative treatments are urgently needed. Human liver organoids are very promising for regenerative medicine; however, organoids are currently cultured in Matrigel, which is extracted from the extracellular matrix of the Engelbreth-Holm-Swarm mouse sarcoma. Matrigel is poorly defined, suffers from high batch-to-batch variability and is of xenogeneic origin, which limits the clinical application of organoids. Here, a novel hydrogel based on polyisocyanopeptides (PIC) and laminin-111 is described for human liver organoid cultures. PIC is a synthetic polymer that can form a hydrogel with thermosensitive properties, making it easy to handle and very attractive for clinical applications. Organoids in an optimized PIC hydrogel proliferate at rates comparable to those observed with Matrigel; proliferation rates are stiffness-dependent, with lower stiffnesses being optimal for organoid proliferation. Moreover, organoids can be efficiently differentiated toward a hepatocyte-like phenotype with key liver functions. This proliferation and differentiation potential maintain over at least 14 passages. The results indicate that PIC is very promising for human liver organoid culture and has the potential to be used in a variety of clinical applications including cell therapy and tissue engineering.
终末期肝病给健康带来的负担日益加重,肝移植是目前唯一的治愈性治疗选择。由于供体肝脏短缺,迫切需要替代治疗方法。人肝脏类器官在再生医学方面极具潜力;然而,类器官目前是在基质胶中培养的,基质胶是从恩格尔布雷特-霍尔姆-斯旺小鼠肉瘤的细胞外基质中提取的。基质胶成分不明确,批次间差异大,且来源于异种,这限制了类器官的临床应用。在此,本文描述了一种基于聚异氰酸肽(PIC)和层粘连蛋白-111的新型水凝胶用于人肝脏类器官培养。PIC是一种合成聚合物,可形成具有热敏特性的水凝胶,便于操作,对临床应用极具吸引力。在优化的PIC水凝胶中的类器官增殖速率与在基质胶中观察到的相当;增殖速率取决于硬度,较低的硬度最适合类器官增殖。此外,类器官可有效地分化为具有关键肝功能的肝细胞样表型。这种增殖和分化潜能至少在传代14次后仍能保持。结果表明,PIC在人肝脏类器官培养方面极具潜力,有潜力用于包括细胞治疗和组织工程在内的多种临床应用。